Logotipo del repositorio
Logotipo del repositorio
 

Diagnostic criteria and management of metabolic syndrome: Evolution overtime

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorRojas, Edward
dc.contributor.authorCastro, Ana
dc.contributor.authorManzano, Alexander
dc.contributor.authorSuarez, Maria Karina
dc.contributor.authorLameda, Victor
dc.contributor.authorCarrasquero, Ruben
dc.contributor.authorNava, Manuel
dc.contributor.authorBermúdez, Valmore
dc.date.accessioned2023-08-15T12:46:21Z
dc.date.available2023-08-15T12:46:21Z
dc.date.issued2020
dc.description.abstractThe beginnings of the Metabolic Syndrome (MetS) as a suspected, not yet recognized entity can be traced back to 1923 when a study concerning a particularly common clustering of metabolic entities observed in diabetic patients was first published. Years of research and endless debate yielded the currently accepted MetS definition and diagnostic criteria, even if some components and their cut-off points are still up for discussion. To date, MetS are defined as a clustering of metabolic risk factors that greatly increase the incidence of cardiovascular disease (CVD) and type 2 diabetes (T2D), while also being closely related to various potentially deadly comorbidities. Furthermore, since early detection and management of MetS have been shown to decrease the risk for CVD and T2D, current research has focused on unifying diagnostic criteria and proposing novel parameters to facilitate MetS identification, while also promoting a healthy lifestyle as a preventive measure. With a deeper understanding of MetS pathophysiology comes the broadening of therapeutic targets open for study, thus expanding and enhancing the treatment methods currently in use. This review aims to summarize the evolution of MetS as a concept, development of the diagnostic criteria, current management, and future directions.eng
dc.description.abstractLos inicios del síndrome metabólico (SM) como una entidad sospechada, si bien no reconocida, datan de 1923, cuando fue publicado un estudio sobre el agrupamiento bastante común de ciertas alteraciones metabólicas en pacientes diabéticos. En las décadas siguientes, la investigación y debates interminables resultaron en la definición y criterios diagnósticos del SM actualmente aceptados, aún si algunos de sus componentes y respectivos puntos de corte siguen en discusión. Hasta la fecha, el SM es definido como un aglomerado de factores de riesgo metabólico que aumentan de gran manera la incidencia de enfermedad cardiovascular (ECV) y diabetes mellitus tipo 2 (DM2), al tiempo que están íntimamente relacionados con diversas comorbilidades potencialmente mortales. Asimismo, debido a que la detección y manejo temprano del SM han demostrado disminuir el riesgo de padecer ECV y DM2, la investigación al respecto se ha enfocado en unificar los criterios diagnósticos y proponer nuevos parámetros que faciliten la identificación del SM, en conjunto con la promoción de un estilo de vida saludable como medida de prevención. El continuo estudio de las bases fisiopatológicas del SM va de la mano con la expansión de blancos terapéuticos a investigar, de esta manera fortaleciendo y mejorando las líneas de tratamiento actualmente en uso. El objetivo de esta revisión es el resumir la evolución del SM como un concepto y sus criterios diagnósticos, haciendo hincapié en su manejo actual y las actualizaciones en lo concerniente a nuevos parámetros diagnósticos y tratamientos innovadores aún en estudio.spa
dc.format.mimetypepdfspa
dc.identifier.citationRojas, D. E., Castro, A., Manzano, A., Suarez, M. K., Lameda, V., Carrasquero, R., Nava, M., & Bermúdez, V. (2020). Diagnostic criteria and management of metabolic syndrome: Evolution overtime. Gaceta Médica De Caracas, 128(4), 480–504. Recuperado a partir de http://saber.ucv.ve/ojs/index.php/rev_gmc/article/view/20628eng
dc.identifier.doihttps://doi.org/10.47307/GMC.2020.128.4.5
dc.identifier.issn27390012
dc.identifier.urihttps://hdl.handle.net/20.500.12442/13137
dc.language.isoengeng
dc.publisherSaber UCV, Universidad Central de Venezuelaspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceGaceta Médica de Caracasspa
dc.sourceVol. 128, No. 2S (2020)
dc.subjectMetabolic syndromeeng
dc.subjectDiagnostic criteriaeng
dc.subjectManagementeng
dc.subjectMetS updateseng
dc.subjectCardiovascular diseaseeng
dc.subjectType 2 diabeteseng
dc.subjectSíndrome metabólicospa
dc.subjectcriterios diagnósticosspa
dc.subjectactualizaciones de SMspa
dc.subjectenfermedad cardiovascularspa
dc.subjectDiabetes Mellitus tipo 2spa
dc.titleDiagnostic criteria and management of metabolic syndrome: Evolution overtimeeng
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesGrundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92(2):399-404.eng
dcterms.referencesGrundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92(2):399-404.eng
dcterms.referencesJames PT, Rigby N, Leach R, International Obesity Task Force. The obesity epidemic, metabolic syndrome, and future prevention strategies. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol. 2004;11(1):3-8.eng
dcterms.referencesDe La Cruz J, Dyzinger W, Herzog S, dos Santos F, Villegas F, Ezinga M. Medicina del Estilo de Vida: Trabajando juntos para revertir la epidemia de las enfermedades crónicas en Latinoamérica. Cienc E Innov En Salud. 2017;4(2):1-7.spa
dcterms.referencesGrundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-2752eng
dcterms.referencesKostapanos M, Florentin M, Elisaf M, Mikhailidis D. Hemostatic Factors and the Metabolic Syndrome. Curr Vasc Pharmacol. 2014;11(6):880-905.eng
dcterms.referencesKraja AT, Province MA, Arnett D, Wagenknecht L, Tang W, Hopkins PN, et al. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutr Metab. 2007;4(1):28.eng
dcterms.referencesSamad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415-3422.eng
dcterms.referencesEdwardson CL, Gorely T, Davies MJ, Gray LJ, Khunti K, Wilmot EG, et al. Association of sedentary behavior with metabolic syndrome: A meta-analysis. PloS One. 2012;7(4):e34916.eng
dcterms.referencesMorales Aguilar R, Lastre-Amell G, Pardo Vásquez A. Estilos de vida relacionados con factores de riesgo cardiovascular. AVFT – Arch Venez Farmacol Ter. 2018;37(2):54-62.spa
dcterms.referencesAgodi A, Maugeri A, Kunzova S, Sochor O, Bauerova H, Kiacova N, et al. Association of Dietary Patterns with Metabolic Syndrome: Results from the Kardiovize Brno 2030 Study. Nutrients. 2018;10(7):898.eng
dcterms.referencesGrundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629-636.eng
dcterms.referencesMozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011;34(1):216-219.eng
dcterms.referencesKatzmarzyk PT, Leon AS, Wilmore JH, Skinner JS, Rao DC, Rankinen T, et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med Sci Sports Exerc. 2003;35(10):1703-1709.eng
dcterms.referencesVargas MÁ, Rosas ME. Impacto de un programa de actividad física aeróbica en adultos mayores con hipertensión arterial. Latinoam Hipertens. 2019;14(2):142-149.spa
dcterms.referencesHe D, Xi B, Xue J, Huai P, Zhang M, Li J. Association between leisure-time physical activity and metabolic syndrome: A meta-analysis of prospective cohort studies. Endocrine. 2014;46(2):231-240.eng
dcterms.referencesGrundy SM. Adipose tissue and metabolic syndrome: Too much, too little or neither. Eur J Clin Invest. 2015;45(11):1209-1217.eng
dcterms.referencesLumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111-2117.eng
dcterms.referencesKlein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, et al. Waist Circumference and Cardiometabolic Risk: A Consensus Statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30(6):1647-1652.eng
dcterms.referencesGrundy SM, Barlow CE, Farrell SW, Vega GL, Haskell WL. Cardiorespiratory fitness and metabolic risk. Am J Cardiol. 2012;109(7):988-993eng
dcterms.referencesFeldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2007;32(1):46-60.eng
dcterms.referencesSrikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. int J Med Ser 2016.13 (1):25-38eng
dcterms.referencesReaven GM. The metabolic syndrome: Is this diagnosis necessary? Am J Clin Nutr. 2006;83(6):1237-1247eng
dcterms.referencesSimmons RK, Alberti KGMM, Gale E a. M, Colagiuri S, Tuomilehto J, Qiao Q, et al. The metabolic syndrome: Useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010;53(4):600-605.eng
dcterms.referencesBremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics. 2012;129(3):557-570.eng
dcterms.referencesKylin E. Studien über das Hypertonie-Hyperglykämie- Hyperurikämie- Syndrom. Z Inn Med. 1923;44:105- 127.eng
dcterms.referencesAlbrink MJ, Meigs JW. Interrelationship between skinfold thickness, serum lipids and blood sugar in normal men. Am J Clin Nutr. 1964;15:255-261.eng
dcterms.referencesWelborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet Lond Engl. 1966;1(7451):1336-1337.eng
dcterms.referencesReaven G, Calciano A, Cody R, Lucas C, Miller R. Carbohydrate intolerant and hyperlipemia in patients with myocardial infarction without known diabetes mellitus. J Clin Endocrinol Metab. 1963;23:1013- 1023.eng
dcterms.referencesCamus JP. [Gout, diabetes, hyperlipemia: A metabolic trisyndrome]. Rev Rhum Mal Osteoartic. 1966;33(1):10-14.eng
dcterms.referencesHammond EC. Some preliminary findings on physical complaints from a prospective study of 1,064,004 men and women. Am J Public Health Nations Health. 1964;54:11-23.eng
dcterms.referencesRuderman NB, Schneider SH, Berchtold P. The “metabolically-obese,” normal-weight individual. Am J Clin Nutr. 1981;34(8):1617-1621.eng
dcterms.referencesMathew H, Farr OM, Mantzoros CS. Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism. 2016;65(1):73-80.eng
dcterms.referencesReaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.eng
dcterms.referencesKaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149(7):1514- 1520.eng
dcterms.referencesZimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology-from West to the rest. Diabetes Care. 1992;15(2):232-252.eng
dcterms.referencesDeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsable for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173-194.eng
dcterms.referencesFerrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416- 422.eng
dcterms.referencesShafrir E. Development and consequences of insulin resistance: Lessons from animals with hyperinsulinemia. Diabetes Metab. 1996;22(2):122- 131.eng
dcterms.referencesMatsuzawa Y. Pathophysiology and molecular mechanisms of visceral fat syndrome: The Japanese experience. Diabetes Metab Rev. 1997;13(1):3-13.eng
dcterms.referencesAlberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med J Br Diabet Assoc. 1998;15(7):539-553.eng
dcterms.referencesGarcía DM, Martínez H, Eblen-Zajjur A, Salinas N. Síndrome metabólico, Estearoil CoA desaturasa y perfil de ácidos grasos en adultos de una comunidad universitaria. Gac Méd Caracas. 2017;125(1):12-23eng
dcterms.referencesKassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: Definitions and controversies. BMC Med. 2011;9:48.eng
dcterms.referencesYach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006;12(1):62-66.eng
dcterms.referencesHossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007;356(3):213-215.eng
dcterms.referencesEngin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. In: Engin AB, Engin A, editors. Obesity and Lipotoxicity [Internet]. Cham: Springer International Publishing; 2017 [cited 2020 Aug 7]. p. 1–17. (Advances in Experimental Medicine and Biology; vol. 960). Available from: http://link. springer.com/10.1007/978-3-319-48382-5_1eng
dcterms.referencesFord ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.eng
dcterms.referencesAzizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract. 2003;61(1):29-37.eng
dcterms.referencesEl Brini O, Akhouayri O, Gamal A, Mesfioui A, Benazzouz B. Prevalence of metabolic syndrome and its components based on a harmonious definition among adults in Morocco. Diabetes Metab Syndr Obes Targets Ther. 2014;7:341-346.eng
dcterms.referencesEl Brini O, Akhouayri O, Gamal A, Mesfioui A, Benazzouz B. Prevalence of metabolic syndrome and its components based on a harmonious definition among adults in Morocco. Diabetes Metab Syndr Obes Targets Ther. 2014;7:341-346.eng
dcterms.referencesMarbou WJT, Kuete V. Prevalence of Metabolic Syndrome and Its Components in Bamboutos Division’s Adults, West Region of Cameroon. BioMed Res Int. 2019;2019:9676984.eng
dcterms.referencesJaspers Faijer-Westerink H, Kengne AP, Meeks KAC, Agyemang C. Prevalence of metabolic syndrome in sub-Saharan Africa: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis NMCD. 2020;30(4):547-565.eng
dcterms.referencesPrasad DS, Kabir Z, Dash AK, Das BC. Prevalence and risk factors for metabolic syndrome in Asian Indians: A community study from urban Eastern India. J Cardiovasc Dis Res. 2012;3(3):204-211.eng
dcterms.referencesChen S-H, Chen S-C, Lai Y-P, Chen P-H, Yeh K-Y. Abdominal obesity and hypertension are correlated with health-related quality of life in Taiwanese adults with metabolic syndrome. BMJ Open Diabetes Res Care. 2020;8(1):e000947.eng
dcterms.referencesHong AR, Lim S. Clinical characteristics of metabolic syndrome in Korea, and its comparison with other Asian countries. J Diabetes Investig. 2015;6(5):508- 515.eng
dcterms.referencesLi Y, Zhao L, Yu D, Wang Z, Ding G. Metabolic syndrome prevalence and its risk factors among adults in China: A nationally representative cross-sectional study. PloS One. 2018;13(6):e0199293.eng
dcterms.referencesHerningtyas EH, Ng TS. Prevalence and distribution of metabolic syndrome and its components among provinces and ethnic groups in Indonesia. BMC Public Health. 2019;19(1):377.eng
dcterms.referencesScuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, et al. Metabolic syndrome across Europe: Different clusters of risk factors. Eur J Prev Cardiol. 2015;22(4):486-491.eng
dcterms.referencesCorbatón-Anchuelo A, Martínez-Larrad MT, Fernández-Pérez C, Vega-Quiroga S, Ibarra-Rueda JM, Serrano-Ríos M, et al. Metabolic syndrome, adiponectin, and cardiovascular risk in Spain (the Segovia study): Impact of consensus societies criteria. Metab Syndr Relat Disord. 2013;11(5):309-318.eng
dcterms.referencesRagino Y, Kovalkova N, Travnikova N, Denisova D, Voevoda M. Prevalence of metabolic syndrome in young adults in Russia. Atherosclerosis. 2017;263:e172.eng
dcterms.referencesSalvi V, D’Ambrosio V, Rosso G, Bogetto F, Maina G. Age-specific prevalence of metabolic syndrome in Italian patients with bipolar disorder. Psychiatry Clin Neurosci. 2011;65(1):47-54.eng
dcterms.referencesVernay M, Salanave B, de Peretti C, Druet C, Malon A, Deschamps V, et al. Metabolic syndrome and socioeconomic status in France: The French Nutrition and Health Survey (ENNS, 2006-2007). Int J Public Health. 2013;58(6):855-864.eng
dcterms.referencesMoebus S, Hanisch J, Bramlage P, Lösch C, Hauner H, Wasem J, et al. Regional differences in the prevalence of the metabolic syndrome in primary care practices in Germany. Dtsch Arzteblatt Int. 2008;105(12):207- 213.eng
dcterms.referencesSetayeshgar S, Whiting SJ, Vatanparast H. Metabolic syndrome in canadian adults and adolescents: Prevalence and associated dietary intake. ISRN Obes. 2012;2012:816846.eng
dcterms.referencesFord ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes. 2010;2(3):180- 193.eng
dcterms.referencesGutiérrez-Solis AL, Datta Banik S, Méndez-González RM. Prevalence of Metabolic Syndrome in Mexico: A Systematic Review and Meta-Analysis. Metab Syndr Relat Disord. 2018;16(8):395-405.eng
dcterms.referencesWong-McClure RA, Gregg EW, Barceló A, Lee K, Abarca-Gómez L, Sanabria-López L, et al. Prevalence of metabolic syndrome in Central America: A crosssectional population-based study. Rev Panam Salud Publica Pan Am J Public Health. 2015;38(3):202-208eng
dcterms.referencesGonzález JP, Martínez RN, González TM de, García RJ, Ugel E, Osuna D, et al. Prevalencia de síndrome metabólico, obesidad y alteración de la glucemia en ayunas en adultos del páramo del Estado Mérida, Venezuela (estudio VEMSOLS). Med Interna. 2011;27(4):262-267.eng
dcterms.referencesValenzuela AA, Maíz A, Margozzini P, Ferreccio C, Rigotti A, Olea R, et al. [Prevalence of metabolic syndrome among Chilean adults]. Rev Med Chil. 2010;138(6):707-714.eng
dcterms.referencesPico SM, Bergonzoli G, Contreras A. Risk factors associated with the metabolic syndrome in Cali, Colombia (2013): A case-control study. Biomed Rev Inst Nac Salud. 2019;39(1):46-54.eng
dcterms.referencesde Carvalho Vidigal F, Bressan J, Babio N, Salas- Salvadó J. Prevalence of metabolic syndrome in Brazilian adults: a systematic review. BMC Public Health. 2013;13:1198.eng
dcterms.referencesDiaz A, Espeche W, March C, Flores R, Parodi R, Genesio MA, et al. [Prevalence of metabolic syndrome in Argentina in the last 25 years: systematic review of population observational studies]. Hipertens Riesgo Vasc. 2018;35(2):64-69.eng
dcterms.referencesRaposo L, Severo M, Barros H, Santos AC. The prevalence of the metabolic syndrome in Portugal: the PORMETS study. BMC Public Health. 2017;17(1):555.eng
dcterms.referencesRaposo L, Severo M, Barros H, Santos AC. The prevalence of the metabolic syndrome in Portugal: the PORMETS study. BMC Public Health. 2017;17(1):555.eng
dcterms.referencesGundogan K, Bayram F, Gedik V, Kaya A, Karaman A, Demir O, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci AMS. 2013;9(2):243- 253.eng
dcterms.referencesChackrewarthy S, Gunasekera D, Pathmeswaren A, Wijekoon CN, Ranawaka UK, Kato N, et al. A Comparison between Revised NCEP ATP III and IDF Definitions in Diagnosing Metabolic Syndrome in an Urban Sri Lankan Population: The Ragama Health Study. ISRN Endocrinol. 2013eng
dcterms.referencesOwolabi EO, Ter Goon D, Adeniyi OV, Ajayi AI. Optimal waist circumference cut-off points for predicting metabolic syndrome among low-income black South African adults. BMC Res Notes. 2018;11(1):22.eng
dcterms.referencesHu H, Kurotani K, Sasaki N, Murakami T, Shimizu C, Shimizu M, et al. Optimal waist circumference cut-off points and ability of different metabolic syndrome criteria for predicting diabetes in Japanese men and women: Japan Epidemiology Collaboration on Occupational Health Study. BMC Public Health. 2016;16:220eng
dcterms.referencesCardinal TR, Vigo A, Duncan BB, Matos SMA, da Fonseca M de JM, Barreto SM, et al. Optimal cutoff points for waist circumference in the definition of metabolic syndrome in Brazilian adults: Baseline analyses of the Longitudinal Study of Adult Health (ELSA-Brasil). Diabetol Metab SynDr. 2018;10:49.eng
dcterms.referencesTorres-Valdez M, Ortiz-Benavides R, Sigüenza-Cruz W, Ortiz-Benavides A, Añez R, Salazar J, et al. Punto de corte de circunferencia abdominal para el agrupamiento de factores de riesgo metabólico: una propuesta para la población adulta de Cuenca, Ecuador. Rev Argent Endocrinol Metab. 2016;53(2):59-66.
dcterms.referencesBermúdez V, Rojas J, Salazar J, Añez R, Chávez- Castillo M, González R, et al. Optimal Waist Circumference Cut-Off Point for Multiple Risk Factor Aggregation: Results from the Maracaibo City Metabolic Syndrome Prevalence Study. Kono S, editor. Epidemiol Res Int. 2014;2014:718571eng
dcterms.referencesVillalobos E, Mata K, Guerrero Y, Añez R, Rojas J, Bermúdez V. Determinación del punto de corte óptimo para la circunferencia abdominal mediante su agregación con múltiples factores de riesgo: una propuesta para la población adulta de San Cristóbal, estado Táchira. Síndr Cardiometabólicospa
dcterms.referencesChang Y-C, Yu Y-H, Chuang L-M. Molecular Genetics of Metabolic Syndrome. In: John Wiley & Sons, Ltd, editor. eLS [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013 [cited 2020 Aug 7]. p. a0024320. Available from: http://doi.wiley.com/10.1002/ 9780470015902.a0024320eng
dcterms.referencesAbou Ziki MD, Mani A. Metabolic syndrome: Genetic insights into disease pathogenesis. Curr Opin Lipidol. 2016;27(2):162-171.eng
dcterms.referencesKong S, Cho YS. Identification of female-specific genetic variants for metabolic syndrome and its component traits to improve the prediction of metabolic syndrome in females. BMC Med Genet. 2019;20(1):99.eng
dcterms.referencesCarson C, Lawson HA. Epigenetics of metabolic syndrome Physiol Genomies. 2018;50(11):947-955eng
dcterms.referencesVassy JL, Shrader P, Yang Q, Liu T, Yesupriya A, Chang M-H, et al. Genetic associations with metabolic syndrome and its quantitative traits by race/ethnicity in the United States. Metab Syndr Relat Disord. 2011;9(6):475-482.eng
dcterms.referencesHeidemann C, Scheidt-Nave C, Richter A, Mensink GBM. Dietary patterns are associated with cardiometabolic risk factors in a representative study population of German adults. Br J Nutr. 2011;106(8):1253-1262.eng
dcterms.referencesLutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syndrome: The Atherosclerosis Risk in Communities study. Circulation. 2008;117(6):754-761.eng
dcterms.referencesSaltzgiver S, Nielson A, Costello H, Baker A, Chan J, Aguilar D. Dietary Determinants of Metabolic Syndrome Parameters Differ by Gender in College Students. Nutrients. 2019;11(12):2892.eng
dcterms.referencesSonnenberg L, Pencina M, Kimokoti R, Quatromoni P, Nam B-H, D’Agostino R, et al. Dietary patterns and the metabolic syndrome in obese and non-obese Framingham women. Obes Res. 2005;13(1):153-162eng
dcterms.referencesViscogliosi G, Cipriani E, Liguori ML, Marigliano B, Saliola M, Ettorre E, et al. Mediterranean dietary pattern adherence: associations with prediabetes, metabolic syndrome, and related microinflammation. Metab Syndr Relat Disord. 2013;11(3):210-216eng
dcterms.referencesLandaeta-Díaz L, Fernández JM, Da Silva-Grigoletto M, Rosado-Alvarez D, Gómez-Garduño A, Gómez- Delgado F, et al. Mediterranean diet, moderate-to-high intensity training, and health-related quality of life in adults with metabolic syndrome. Eur J Prev Cardiol. 2013;20(4):555-564.eng
dcterms.referencesYoon YS, Oh SW, Baik HW, Park HS, Kim WY. Alcohol consumption and the metabolic syndrome in Korean adults: the 1998 Korean National Health and Nutrition Examination Survey. Am J Clin Nutr. 2004;80(1):217-224.eng
dcterms.referencesAlkerwi A, Boutsen M, Vaillant M, Barre J, Lair M-L, Albert A, et al. Alcohol consumption and the prevalence of metabolic syndrome: A metaanalysis of observational studies. Atherosclerosis. 2009;204(2):624-635.eng
dcterms.referencesFreiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R. Alcohol Consumption and the Prevalence of the Metabolic Syndrome in the U.S.: A crosssectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2954-2959.eng
dcterms.referencesFreiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R. Alcohol Consumption and the Prevalence of the Metabolic Syndrome in the U.S.: A crosssectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2954-2959.eng
dcterms.references2015;2015:1-13. Kim SK, Hong S-H, Chung J-H, Cho KB. Association Between Alcohol Consumption and Metabolic Syndrome in a Community-Based Cohort of Korean Adults. Med Sci Monit Int Med J Exp Clin Res. 2017;23:2104-2110.eng
dcterms.referencesGrosso G, Stepaniak U, Micek A, Topor-Mądry R, Pikhart H, Szafraniec K, et al. Association of daily coffee and tea consumption and metabolic syndrome: results from the Polish arm of the HAPIEE study. Eur J Nutr. 2015;54(7):1129-1137.eng
dcterms.referencesGrosso G, Stepaniak U, Micek A, Topor-Mądry R, Pikhart H, Szafraniec K, et al. Association of daily coffee and tea consumption and metabolic syndrome: results from the Polish arm of the HAPIEE study. Eur J Nutr. 2015;54(7):1129-1137.eng
dcterms.referencesStutz B, Ahola AJ, Harjutsalo V, Forsblom C, Groop P-H. Association between habitual coffee consumption and metabolic syndrome in type 1 diabetes. Nutr Metab Cardiovasc Dis. 2018;28(5):470-476.eng
dcterms.referencesSun K, Liu J, Ning G. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PloS One. 2012;7(10):e47791.eng
dcterms.referencesOlsen RH, Krogh-Madsen R, Thomsen C, Booth FW, Pedersen BK. Metabolic responses to reduced daily steps in healthy non-exercising men. JAMA. 2008;299(11):1261-1263.eng
dcterms.referencesHelmerhorst HJF, Wijndaele K, Brage S, Wareham NJ, Ekelund U. Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity. Diabetes. 2009;58(8):1776-1779.eng
dcterms.referencesBlanck HM, McCullough ML, Patel AV, Gillespie C, Calle EE, Cokkinides VE, et al. Sedentary behavior, recreational physical activity, and 7-year weight gain among postmenopausal U.S. women. Obes Silver Spring Md. 2007;15(6):1578-1588.eng
dcterms.referencesOrtiz R, Bermúdez V, Torres M, Guzmán Lozada JA, Valdiviezo Romero AJ, Castillo Cueva OL, et al. La actividad física de ocio como factor protector para la obesidad en la población adulta del área rural de Quingeo, Cuenca-Ecuador. AVFT – Arch Venez Farmacol Ter. 2018;37(1):42-46.eng
dcterms.referencesHan TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016;5:2048004016633371.eng
dcterms.referencesChacín M, Carrillo S, Rodríguez JE, Salazar J, Rojas J, Añez R, et al. Obesidad Infantil: Un problema de pequeños que se está volviendo grande. Latinoam Hipertens. 2019;14(5):616-623.spa
dcterms.referencesMantilla Morrón M. Frecuencia de Obesidad y Sobrepeso en una Institución de Salud de la Ciudad de Barranquilla. Cienc E Innov En Salud. 2013;1(1):33- 39.spa
dcterms.referencesGotera J, Valero N, Ávila A, Mosquera J, Linares J, Amell de Diaz A, et al. Comportamiento epidemiológico de las dislipidemias en pacientes del Instituto de Investigaciones Endocrino-Metabólicas Dr. Félix Gómez, Venezuela. Rev Latinoam Hipertens. Gac Méd Caracas 499 2019;14(5):601-608.spa
dcterms.referencesCórdova-Pluma VH, Castro-Martínez G, Rubio- Guerra A, Hegewisch ME. A Brief Chronic of Metabolic Syndrome Definition. Med Interna México. 2014;30(3):312-328.eng
dcterms.referencesAlberti G. Introduction to the metabolic syndrome. Eur Heart J Suppl. 2005;7(suppl_D): D3-5.eng
dcterms.referencesKemp HG. Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. Am J Cardiol. 1973;32(3):375-376.eng
dcterms.referencesBalkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med J Br Diabet Assoc. 1999;16(5):442-443.eng
dcterms.referencesWood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998;140(2):199-270.eng
dcterms.referencesLean ME, Han TS, Seidell JC. Impairment of health and quality of life in people with large waist circumference. Lancet Lond Engl. 1998;351(9106):853-856.eng
dcterms.referencesSarafidis PA, Nilsson PM. The metabolic syndrome: A glance at its history. J Hypertens. 2006;24(4):621- 662.eng
dcterms.referencesExpert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.eng
dcterms.referencesAcosta GA, Álvarez AM, Baldovino FB, Briceño CE, Pérez-Ybarra LM, Barrera GJ, et al. Evaluación de vitamina D, biomarcadores de inflamación y factores de riesgo cardiovascular en pacientes con hipertensión arterial. AVFT – Arch Venez Farmacol Ter. 2018;37(4):360-367.spa
dcterms.referencesSierra-Castrillo J, Gómez-Rave LJ, Cardenas- Sierra DM, Villán-Bustamante N, Acosta-León NP, Bermúdez-Pirela V. Correlación entre niveles de hormonas tiroideas y concentración sérica de interleucina 6 (IL-6), proteína C reactiva (PCR) y lactato deshidrogenasa (LDH), en pacientes con diabetes tipo 2. Cienc E Innov En Salud. 2020;e77:76- 91.spa
dcterms.referencesEinhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2003;9(3):237- 252.eng
dcterms.referencesAlberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059-1062.eng
dcterms.referencesAlberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.eng
dcterms.referencesEspinoza Diaz CI, Morocho Zambrano A de los Á, Neira Borja JE, Morales Carrasco AP, Moyano Brito EG, Toala Guerrero JE, et al. Prevalencia de HDL-C bajas en adultos mayores de la parroquia de Baños, Cuenca. Latinoam Hipertens. 2018;13(5):492-495.spa
dcterms.referencesde Abreu VG, Martins CJ de M, de Oliveira PAC, Francischetti EA. High-molecular-weight adiponectin/ HOMA-IR ratio as a biomarker of metabolic syndrome in urban multiethnic Brazilian subjects. Hribal ML, editor. PLOS ONE. 2017;12(7):e0180947eng
dcterms.referencesKozłowska L, Rydzewski A, Fiderkiewicz B, Wasińska-Krawczyk A, Grzechnik A, Rosołowska- Huszcz D. Adiponectin, resistin and leptin response to dietary intervention in diabetic nephropathy. J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found. 2010;20(4):255-262.eng
dcterms.referencesEl Husseny MWA, Mamdouh M, Shaban S, Ibrahim Abushouk A, Zaki MMM, Ahmed OM, et al. Adipokines: Potential Therapeutic Targets for Vascular Dysfunction in Type II Diabetes Mellitus and Obesity. J Diabetes Res. 2017;2017:8095926.eng
dcterms.referencesZhang H-W, Zhao X, Guo Y-L, Zhu C-G, Wu N-Q, Sun J, et al. Free fatty acids and cardiovascular outcome: a Chinese cohort study on stable coronary artery disease. Nutr Metab. 2017;14(1):41. 125. Ashmaig M, Ashmeik K, Ahmed A, Sobki S, Abdulla M. Levels of apolipoproteins as risk factors for coronary artery disease. J Vasc Bras. 2011;10(4):293-eng
dcterms.referencesYing X, Jiang Y, Qin G, Qian Y, Shen X, Jiang Z, et al. Association of body mass index, waist circumference, and metabolic syndrome with serum cystatin C in a Chinese population. Medicine (Baltimore). 2017;96(10):e6289.eng
dcterms.referencesYadav D, Choi E, Ahn SV, Baik SK, Cho Y zoo, Koh SB, et al. Incremental Predictive Value of Serum AST-to-ALT Ratio for Incident Metabolic Syndrome: The ARIRANG Study. Lu S-N, editor. PLOS ONE. 2016;11(8):e0161304.eng
dcterms.referencesChang H-W, Chang J-B, Li P-F, Chen J-H, Huang C-L, Liang Y-J, et al. The association of hematological parameters and metabolic syndrome in an older population: A cross-sectional and longitudinal study. J Med Sci. 2016;36(5):180.eng
dcterms.referencesYoon K, Ryu S, Lee J, Park J-D. Higher and increased concentration of hs-CRP within normal range can predict the incidence of metabolic syndrome in healthy men. Diabetes Metab SynDr. 2018;12(6):977-983.eng
dcterms.referencesGanguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.eng
dcterms.referencesBulusu S, Sharma M. What does serum γ-glutamyltransferase tell us as a cardiometabolic risk marker? Ann Clin Biochem. 2016;53(Pt 3):312- 332.eng
dcterms.referencesO’Neill S, Bohl M, Gregersen S, Hermansen K, O’Driscoll L. Blood-Based Biomarkers for Metabolic Syndrome. Trends Endocrinol Metab TEM. 2016;27(6):363-374.eng
dcterms.referencesvon Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther. 2014;144(1):41-49.eng
dcterms.referencesLihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004;219(1-2):9-15.eng
dcterms.referencesLi P, Jiang R, Li L, Liu C, Yang F, Qiu Y. Correlation of serum adiponectin and adiponectin gene polymorphism with metabolic syndrome in Chinese adolescents. Eur J Clin Nutr. 2015;69(1):62-67.eng
dcterms.referencesKarolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SLT, Wong MTK, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012;97(12):E2271-2276eng
dcterms.referencesWang Y-T, Tsai P-C, Liao Y-C, Hsu C-Y, Juo S-HH. Circulating microRNAs have a sex-specific association with metabolic syndrome. J Biomed Sci. 2013;20:72eng
dcterms.referencesParikh R, Mohan V, Joshi S. Should waist circumference be replaced by index of central obesity (ICO) in definition of metabolic syndrome? Diabetes Metab Res Rev. 2012;28(1):3-5.eng
dcterms.referencesAbdullah A, Abd El-Baky A, Bakry S, Abd-El Hay E. Adiponectin and liptin levels and their risk in coronary artery diseases in obese Egyptian men. Res J Med Med Sci. 2009;4(2):526-532.eng
dcterms.referencesAjay VS, Prabhakaran D, Jeemon P, Thankappan KR, Mohan V, Ramakrishnan L, et al. Prevalence and determinants of diabetes mellitus in the Indian industrial population. Diabet Med. 2008;25(10):1187– 94.eng
dcterms.referencesOrtiz R, Salas Ramirez FN, López Pérez SJ, Rojas Lojano MG, Rodas Méndez OJ, Sinchi Suquilanda JC, et al. Índice cintura cadera y presión arterial en las poblaciones rurales de Cumbe y Quingeo, Ecuador. Latinoam Hipertens. 2018;13(4):396-369.spa
dcterms.referencesBrowning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev. 2010;23(2):247-269.eng
dcterms.referencesBaveicy K, Mostafaei S, Darbandi M, Hamzeh B, Najafi F, Pasdar Y. Predicting Metabolic Syndrome by Visceral Adiposity Index, Body Roundness Index and a Body Shape Index in Adults: A Cross-Sectional Study from the Iranian RaNCD Cohort Data. Diabetes Metab Syndr Obes Targets Ther. 2020;13:879-887.eng
dcterms.referencesBaveicy K, Mostafaei S, Darbandi M, Hamzeh B, Najafi F, Pasdar Y. Predicting Metabolic Syndrome by Visceral Adiposity Index, Body Roundness Index and a Body Shape Index in Adults: A Cross-Sectional Study from the Iranian RaNCD Cohort Data. Diabetes Metab Syndr Obes Targets Ther. 2020;13:879-887.eng
dcterms.referencesMa C-M, Lu N, Wang R, Liu X-L, Lu Q, Yin F-Z. Three novel obese indicators perform better in monitoring the management of metabolic syndrome in type 2 diabetes. Sci Rep. 2017;7(1):9843.eng
dcterms.referencesRay L, Ravichandran K, Nanda SK. Comparison of Lipid Accumulation Product Index with Body Mass Index and Waist Circumference as a Predictor of Metabolic Syndrome in Indian Population. Metab Syndr Relat Disord. 2018;16(5):240-245.eng
dcterms.referencesCheng Y-L, Wang Y-J, Lan K-H, Huo T-I, Huang Y-H, Su C-W, et al. Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. Gastroenterol Res Pract. 2017;2017:9279836.eng
dcterms.referencesGrundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364-373.eng
dcterms.referencesDunkley AJ, Davies MJ, Stone MA, Taub NA, Troughton J, Yates T, et al. The Reversal Intervention for Metabolic Syndrome (TRIMS) study: rationale, design, and baseline data. Trials. 2011;12:107.eng
dcterms.referencesAguilar-Salinas CA, Viveros-Ruiz T. Recent advances in managing/understanding the metabolic syndrome. F1000Research. 2019;8:F1000 Faculty Rev-370.eng
dcterms.referencesAspry KE, Van Horn L, Carson JAS, Wylie-Rosett J, Kushner RF, Lichtenstein AH, et al. Medical Nutrition Education, Training, and Competencies to Advance Guideline-Based Diet Counseling by Physicians: A Science Advisory From the American Heart Association. Circulation. 2018;137(23):e821- 841.eng
dcterms.referencesYoneda M, Yamane K, Jitsuiki K, Nakanishi S, Kamei N, Watanabe H, et al. Prevalence of metabolic syndrome compared between native Japanese and Japanese-Americans. Diabetes Res Clin Pract. 2008;79(3):518-522.eng
dcterms.referencesRuidavets J-B, Bongard V, Dallongeville J, Arveiler D, Ducimetière P, Perret B, et al. High consumptions of grain, fish, dairy products and combinations of these are associated with a low prevalence of metabolic syndrome. J Epidemiol Community Health. 2007;61(9):810-817.eng
dcterms.referencesHaseeb S, Alexander B, Baranchuk A. Wine and Cardiovascular Health: A Comprehensive Review. Circulation. 2017;136(15):1434-1448.eng
dcterms.referencesLiu L, Wang Y, Lam KSL, Xu A. Moderate wine consumption in the prevention of metabolic syndrome and its related medical complications. Endocr Metab Immune Disord Drug Targets. 2008;8(2):89-98.eng
dcterms.referencesPark Y-MM, Steck SE, Fung TT, Zhang J, Hazlett LJ, Han K, et al. Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH) style diet, and metabolic health in U.S. adults. Clin Nutr Edinb Scotl. 2017;36(5):1301-1309.eng
dcterms.referencesSoltani S, Arablou T, Jayedi A, Salehi-Abargouei A. Adherence to the dietary approaches to stop hypertension (DASH) diet in relation to all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective cohort studies. Nutr J. 2020;19(1):37.eng
dcterms.referencesGershuni VM, Yan SL, Medici V. Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome. Curr Nutr Rep. 2018;7(3):97-106.eng
dcterms.referencesBueno NB, de Melo ISV, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: A metaanalysis of randomized controlled trials. Br J Nutr. 2013;110(7):1178-1187.eng
dcterms.referencesSantos FL, Esteves SS, da Costa Pereira A, Yancy WS, Nunes JPL. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev Off J Int Assoc Study Obes. 2012;13(11):1048-1066.eng
dcterms.referencesEbbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-Lago E, et al. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA. 2012;307(24):2627-2634.eng
dcterms.referencesPaoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: A review of the therapeutic uses of verylow- carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013;67(8):789-796.eng
dcterms.referencesVolek JS, Sharman MJ, Forsythe CE. Modification of lipoproteins by very low-carbohydrate diets. J Nutr. 2005;135(6):1339-1342.eng
dcterms.referencesFoster GD, Wyatt HR, Hill JO, Makris AP, Rosenbaum DL, Brill C, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med. 2010;153(3):147- 157.eng
dcterms.referencesColberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity/ Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079.eng
dcterms.referencesBalk EM, Earley A, Raman G, Avendano EA, Pittas AG, Remington PL. Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. Ann Intern Med. 2015;163(6):437-451. Dempsey PC, Owen N, Biddle SJH, Dunstan DW. Managing sedentary behavior to reduce the risk of diabetes and cardiovascular disease. Curr Diab Rep. 2014;14(9):522.eng
dcterms.referencesBiswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: A systematic review and meta-analysis. Ann Intern Med. 2015;162(2):123-132.eng
dcterms.referencesWilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: Systematic review and meta-analysis. Diabetologia. 2012;55(11):2895-2905.eng
dcterms.referencesAldawudi I, Katwal PC, Jirjees S, Htun ZM, Khan S. Future of Bariatric Embolization: A Review of Upto- date Clinical Trials. Cureus. 2020;12(5):e7958.eng
dcterms.referencesGenser L, Barrat C. [Long term outcomes after bariatric and metabolic surgery]. Presse Medicale Paris Fr 1983. 2018;47(5):471-479.eng
dcterms.referencesBaltasar A, Bou R, Bengochea M, Serra C, Ferri L, Pérez N, et al. Four decades of bariatric surgery in a community hospital of Spain. Nutr Hosp. 2017;34(4):980-988.eng
dcterms.referencesKhosravi-Largani M, Nojomi M, Aghili R, Otaghvar HA, Tanha K, Seyedi SHS, et al. Evaluation of all Types of Metabolic Bariatric Surgery and its Consequences: A Systematic Review and Meta-Analysis. Obes Surg. 2019;29(2):651-690.eng
dcterms.referencesBuchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):17241737.eng
dcterms.referencesSabench Pereferrer F, Domínguez-Adame Lanuza E, Ibarzabal A, Socas Macias M, Valentí Azcárate V, García Ruiz de Gordejuela A, et al. Criterios de calidad en cirugía bariátrica: revisión de conjunto y recomendaciones de la Asociación Española de Cirujanos y de la Sociedad Española de Cirugía de la Obesidad. Cir Esp. 2017;95(1):4-16.eng
dcterms.referencesBuchwald H, Buchwald JN. Metabolic (Bariatric and Nonbariatric) Surgery for Type 2 Diabetes: A Personal Perspective Review. Diabetes Care. 2019;42(2):331- 340.eng
dcterms.referencesSyed MI, Morar K, Shaikh A, Craig P, Khan O, Patel S, et al. Gastric Artery Embolization Trial for the Lessening of Appetite Nonsurgically (GET LEAN): Six-Month Preliminary Data. J Vasc Interv Radiol. 2016;27(10):1502-1508.eng
dcterms.referencesFu Y, Kraitchman DL. Rationale and Preclinical Data Supporting Bariatric Arterial Embolization. Tech VascInterv Radiol. 2020;23(1):100656eng
dcterms.referencesHafezi-Nejad N, Bailey CR, Gunn AJ, Weiss CR. Weight Loss after Left Gastric Artery Embolization: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2019;30(10):1593-1603.e3.eng
dcterms.referencesHafezi-Nejad N, Bailey CR, Weiss CR. Bariatric Embolization: A Narrative Review of Clinical Data From Human Trials. Tech Vasc Interv Radiol. 2020;23(1):100658.eng
dcterms.referencesIsraili ZH, Lyoussi B, Hernández-Hernández R, Velasco M. Metabolic syndrome: treatment of hypertensive patients. Am J Ther. 2007;14(4):386- 402.eng
dcterms.referencesChobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.eng
dcterms.referencesJames PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507.eng
dcterms.referencesUnger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357.eng
dcterms.referencesSowers JR. Treatment of hypertension in patients with diabetes. Arch Intern Med. 2004;164(17):1850-1857.eng
dcterms.referencesVald O, Ch E, Barrera FMT. Comportamiento de las Crisis Hipertensivas en un Grupo de Pacientes Hipertensos. Cienc E Innov En Salud. 2014;2(1):40- 45.eng
dcterms.referencesRojas E, Velasco M, Bermúdez V, Israili Z, Bolli P. Targeting hypertension in patients with cardiorenal metabolic syndrome. Curr Hypertens Rep. 2012;14(5):397-402.eng
dcterms.referencesEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet Lond Engl. 2000;355(9200):253-259.eng
dcterms.referencesAmerican Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011;34 Suppl 1:S11-61. 190. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3-11.eng
dcterms.referencesSirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3-11.eng
dcterms.referencesTokgözoglu L, Zamorano JL. Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. Drugs Context. 2020;9:2020-4–4.eng
dcterms.referencesCarmena R, Betteridge DJ. Diabetogenic Action of Statins: Mechanisms. Curr Atheroscler Rep.2019;21(6):23.eng
dcterms.referencesIto MK. The metabolic syndrome: Pathophysiology, clinical relevance, and use of niacin. Ann Pharmacother. 2004;38(2):277-285.eng
dcterms.referencesLloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785-1822.eng
dcterms.referencesArnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376-1414.eng
dcterms.referencesBinesh Marvasti T, Adeli K. Pharmacological management of metabolic syndrome and its lipid complications. Daru J Fac Pharm Tehran Univ Med Sci. 2010;18(3):146-154.eng
dcterms.referencesRojas J, Añez R, Martínez MS, Ochoa M, Salazar J, Calvo MJ, et al. A tale about perfect partners: New horizons in glimepiride and metformin Mechanisms of action. AVFT – Arch Venez Farmacol Ter. 2016;35(2):53-66.eng
dcterms.referencesNúñez Troconis J. Uso de la metformina en obstetricia. Gac Méd Caracas. 2020;128(2):139-158.eng
dcterms.referencesStover L, Chi J, Kelsberg G, Safranek S. Which patients with metabolic syndrome benefit from metformin? J Fam Pract. 2016;65(11):832-834.eng
dcterms.referencesOrchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611- 619.eng
dcterms.referencesNieuwdorp M, Stroes ESG, Kastelein JJP, Fenofibrate/ Metformin Study Group. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes Obes Metab. 2007;9(6):869- 878.eng
dcterms.referencesDerosa G, D’Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J. 2007;37(2):79-86.eng
dcterms.referencesNanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: A critical review. Bioorganic Chem. 2018;77:548-567.eng
dcterms.referencesBragt MCE, Popeijus HE. Peroxisome proliferatoractivated receptors and the metabolic syndrome. Physiol Behav. 2008;94(2):187-197.eng
dcterms.referencesSolymár M, Ivic I, Pótó L, Hegyi P, Garami A, Hartmann P, et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis. PloS One. 2018;13(11):e0207947.eng
dcterms.referencesAmerican Diabetes Association. 6. Obesity Management for the Treatment of Type 2 Diabetes. Diabetes Care. 2016;39 Suppl 1:S47-51.eng
dcterms.referencesYe J, Wu Y, Li F, Wu T, Shao C, Lin Y, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Ther Adv Gastroenterol. 2019;12:1756284819879047.eng
dcterms.referencesShirai K, Fujita T, Tanaka M, Fujii Y, Shimomasuda M, Sakai S, et al. Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study. Adv Ther. 2019;36(1):86- 100.eng
dcterms.referencesGorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz- Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. Int J Clin Pract. 2019;73(11):e13399.eng
dcterms.referencesPasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitaryadrenal axis in humans. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2000;32(11– 12):521-525.eng
dcterms.referencesParedes S, Ribeiro L. Cortisol: the villain in metabolic syndrome? Rev Assoc Medica Bras 1992. 2014;60(1):84-92.eng
dcterms.referencesHashimoto T, Igarashi J, Hasan AU, Ohmori K, Kohno M, Nagai Y, et al. Mifepristone Promotes Adiponectin Production and Improves Insulin Sensitivity in a Mouse Model of Diet-Induced-Obesity. Oster H, editor. PLoS ONE. 2013;8(11):e79724.eng
dcterms.referencesNikolic I, Vujicic M, Saksida T, Berki T, Stosic- Grujicic S, Stojanovic I. The role of endogenous glucocorticoids in glucose metabolism and immune status of MIF-deficient mice. Eur J Pharmacol. 2013;714(1–3):498-506.eng
dcterms.referencesPriyadarshini E, Anuradha CV. Glucocorticoid Antagonism Reduces Insulin Resistance and Associated Lipid Abnormalities in High-Fructose-Fed Mice. Can J Diabetes. 2017;41(1):41-51.eng
dcterms.referencesBernal-Sore I, Navarro-Marquez M, Osorio-Fuentealba C, Díaz-Castro F, del Campo A, Donoso-Barraza C, et al. Mifepristone enhances insulin-stimulated Akt phosphorylation and glucose uptake in skeletal musclecells. Mol Cell Endocrinol. 2018;461:277-283.eng
dcterms.referencesBiolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: From sarcopenic obesity to cachexia. Clin Nutr Edinb Scotl. 2014;33(5):737-748.eng
dcterms.referencesBaumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107(2):123-136.eng
dcterms.referencesManini TM, Clark BC. Dynapenia and Aging: An Update. J Gerontol Ser A. 2012;67A(1):28-40.eng
dcterms.referencesWalsh MC, Hunter GR, Livingstone MB. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2006;17(1):61-67.eng
dcterms.referencesUrban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol- Endocrinol Metab. 1995;269(5):E820-26.eng
dcterms.referencesBhasin S, Woodhouse L, Storer T. Proof of the effect of testosterone on skeletal muscle. J Endocrinol. 2001;170(1):27-38.eng
dcterms.referencesHackett G. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. Sex Med Rev. 2019;7(3):476-490.eng
dcterms.referencesHallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-Hashiani A, Ayubi E, et al. The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta-analysis of observational studies. Lupus. 2018;27(6):899-912.eng
dcterms.referencesPuenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med. 2009;121(6):9-20.eng
dcterms.referencesBell-Anderson KS. Adipokines: Linking obesity and cardiovascular disease. Expert Rev Endocrinol Metab. 2008;3(1):61-73.eng
dcterms.referencesZhu Q, Scherer PE. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat Rev Nephrol. 2018;14(2):105-120.eng
dcterms.referencesBao P, Liu G, Wei Y. Association between IL-6 and related risk factors of metabolic syndrome and cardiovascular disease in young rats. Int J Clin Exp Med. 2015;8(8):13491-13499.eng
dcterms.referencesMok CC. The Jakinibs in systemic lupus erythematosus:progress and prospects. Expert Opin Investig Drugs. 2019;28(1):85-92.eng
dcterms.referencesAmerican Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Supplement 1): S98-110.eng
dcterms.referencesSchiotis RE, Buzoianu AD, Mureșanu DF, Suciu S. New pharmacological strategies in rheumatic diseases. J Med Life. 2016;9(3):227-234.eng
dcterms.referencesvan Raalte DH, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJW, Ackermans MT, et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomized controlled trial. Diabetologia. 2011;54(8):21032112.eng
dcterms.referencesToms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross-sectional study. Arthritis Res Ther. 2009;11(4):R110.eng
dcterms.referencesRidker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;380(8):752-762.eng
dcterms.referencesSolomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between diseasemodifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531.eng
dcterms.referencesRekedal LR, Massarotti E, Garg R, Bhatia R, Gleeson T, Lu B, et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010;62(12):3569-3573.eng
dcterms.referencesStagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta-cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14(3):R141eng
dcterms.referencesMandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6(3):158-166eng
dcterms.referencesLarsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517-1526.eng
dcterms.referencesEsser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015;24(3):283-307.eng
dcterms.referencesSchultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signaling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS One. 2010;5(12):e14328.eng
dcterms.referencesOgata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, et al. Improvement of HbA1c during treatment with humanized anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis. 2011;70(6):1164-1165.eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
03_2021_GC_ART_Diagnostic criteria.pdf
Tamaño:
279.46 KB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca